Skip to main
FBRX

Forte Biosciences (FBRX) Stock Forecast & Price Target

Forte Biosciences (FBRX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Forte Biosciences Inc. is poised for a positive outlook as it advances its product candidate, FB-102, through preclinical trials, targeting a range of autoimmune conditions with significant unmet needs and market potential. The company's increased R&D expenses, rising from $5.9 million to $15.2 million year-over-year, reflect a commitment to clinical and manufacturing advancements that could enhance its competitive positioning in the therapeutic landscape. Additionally, the untapped nature of markets for conditions like graft-versus-host disease and vitiligo suggests strong prospects for market share capture, particularly if FB-102 can avoid adverse effects associated with existing therapies.

Bears say

Forte Biosciences faces significant challenges due to intense market competition from both existing and emerging therapies targeting similar autoimmune conditions, which could adversely affect its market penetration and pricing strategy. Delays in the clinical development process, regulatory approvals, or commercialization timelines are anticipated, potentially leading to prolonged development periods and higher costs. Furthermore, the company's FB-102 has demonstrated low efficacy in a Phase Ib study, raising concerns about its comparative performance against competitors and the soundness of its study design.

Forte Biosciences (FBRX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Forte Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Forte Biosciences (FBRX) Forecast

Analysts have given Forte Biosciences (FBRX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Forte Biosciences (FBRX) has a Strong Buy consensus rating as of Jan 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Forte Biosciences (FBRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.